glp-1 receptor agonists and cancer risk in adults with obesity Study Finds May Reduce In a major new JAMA
Description
J Clin Gastroenterol 2021;55:586-93.PubMed 111
Notably, these medications are extremely expensive, insurance coverage is variable and the U.S
Martins et al
Recent Findings Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia
This means hydroxyzine (25-50mg) for oral sedation and ondansetron (4mg) for intravenous sedation
Under this scheme, selected medicines may receive a significantly shortened review timeline
